Lantheus Holdings posts third quarter revenue of $384.0 million

Reuters
2025/11/06
Lantheus Holdings posts third quarter revenue of $384.0 million

Lantheus Holdings Inc. reported worldwide revenue of $384.0 million for the third quarter of 2025. The company recorded GAAP fully diluted earnings per share of $0.41 and adjusted fully diluted earnings per share of $1.27. Free cash flow for the quarter was $94.7 million. During the period, Lantheus closed the acquisition of Life Molecular Imaging, expanding its commercial portfolio and capabilities in nuclear medicine. The company also announced upcoming PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent, MK-6240 tau-targeted PET imaging agent, and LNTH-2501 Ga 68 PET diagnostic imaging kit. Additionally, Lantheus disclosed a leadership transition plan, with CEO Brian Markison set to retire at the end of 2025 and the board initiating a CEO search.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570061-en) on November 06, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10